SCHEMBL19657807

SCHEMBL19657807

Cc1nc(N)cc2cnccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CLK1 P49759 2/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
HASPIN Q8TF76 7/20 0.42
IMPDH2 P12268 3/20 0.42
GSK3B P49841 1/20 0.41
ABL1 P00519 1/20 0.40
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
PRKCZ Q05513 1/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18266936 0.80 CLK1 (0.39) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL27932280 0.77 IMPDH2 (0.50) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5798814 0.77 IMPDH2 (0.50) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL19044754 0.77 HASPIN (0.38) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL30282821 0.77 HASPIN (0.43) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL27051688 0.77 HASPIN (0.43) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL2595823 0.74 BACE1 (0.52) CYP1A2CYP3A4NOS3NOS1NOS2
SCHEMBL11365647 0.73 LMNA (0.44) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL27109641 0.69 HIPK2 (0.41) LMNACYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL7751472 0.69 CYP2A6 (0.57) LMNACYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464270-B1 HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER GENENTECH INC (US) 2022-02-23 EP disclosed
WO-2017205536-A2 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 WO disclosed